Literature DB >> 33968441

Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review.

Robin J Lurvink1, Koen P Rovers1, Simon W Nienhuijs1, Geert-Jan Creemers2, Jacobus W A Burger1, Ignace H J de Hingh1,3.   

Abstract

Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) is increasingly used as a palliative treatment option for patients with colorectal peritoneal metastases (CPM). The present study aimed to systematically review all clinical studies reporting safety and efficacy outcomes of PIPAC-OX in patients with CPM. PubMed, EMBASE, The Cochrane Library, and CINAHL were systematically searched to identify all clinical studies that included at least one patient with CPM treated with PIPAC-OX and reported one of the following outcomes: adverse events, tumor response, quality of life, secondary cytoreductive surgery, progression-free survival, overall survival, and environmental safety of PIPAC-OX. Results were narratively described. Of 28 included studies, only 14 non-comparative studies separately reported at least one outcome of PIPAC-OX for CPM, of which only two studies specifically focused on this group. These 14 studies reported adverse events (5 studies), tumor response (5 studies), secondary cytoreductive surgery (4 studies), progression-free survival (1 study), overall survival (5 studies), and environmental safety (2 studies). Except for 5 studies (describing 26 patients), none of the included studies stratified their results for PIPAC-OX monotherapy and PIPAC-OX with concomitant systemic therapy, and none of the studies reporting survival outcomes stratified results for line of palliative treatment, complicating interpretation. No PIPAC-OX related deaths were reported. No occupational platinum was detected during PIPAC-OX. The available evidence regarding PIPAC-OX for CPM is limited and difficult to interpret. Despite these limitations, PIPAC-OX appears safe in patients with CPM and safe for operating personnel. To increase insight in the role of PIPAC-OX in this setting, investigators of ongoing and future studies are encouraged to report separate outcomes of PIPAC-OX for CPM, to stratify their results for PIPAC-OX monotherapy and PIPAC-OX with concomitant systemic therapy, and to stratify survival results for line of palliative treatment. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Pressurized intraperitoneal aerosol chemotherapy (PIPAC); colorectal cancer; oxaliplatin; peritoneal metastases

Year:  2021        PMID： 33968441      PMCID： PMC8100707          DOI： 10.21037/jgo-20-257

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  48 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

Review 2.  Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications.

Authors:  Mohammad Alyami; Martin Hübner; Fabian Grass; Naoual Bakrin; Laurent Villeneuve; Nathalie Laplace; Guillaume Passot; Olivier Glehen; Vahan Kepenekian
Journal:  Lancet Oncol       Date:  2019-07       Impact factor: 41.316

3.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Authors:  Jan Franko; Qian Shi; Jeffrey P Meyers; Timothy S Maughan; Richard A Adams; Matthew T Seymour; Leonard Saltz; Cornelis J A Punt; Miriam Koopman; Christophe Tournigand; Niall C Tebbutt; Eduardo Diaz-Rubio; John Souglakos; Alfredo Falcone; Benoist Chibaudel; Volker Heinemann; Joseph Moen; Aimery De Gramont; Daniel J Sargent; Axel Grothey
Journal:  Lancet Oncol       Date:  2016-10-12       Impact factor: 41.316

4.  Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.

Authors:  Maciej Nowacki; Mohammad Alyami; Laurent Villeneuve; Frederic Mercier; Martin Hubner; Wouter Willaert; Wim Ceelen; Marc Reymond; Denis Pezet; Catherine Arvieux; Vladimir Khomyakov; Laura Lay; Sergio Gianni; Wojciech Zegarski; Naoual Bakrin; Olivier Glehen
Journal:  Eur J Surg Oncol       Date:  2018-02-22       Impact factor: 4.424

Review 5.  Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Mohammad Alyami; Frederic Mercier; Matthieu Siebert; Pierre-Emmanuel Bonnot; Nathalie Laplace; Laurent Villeneuve; Guillaume Passot; Olivier Glehen; Naoual Bakrin; Vahan Kepenekian
Journal:  Eur J Surg Oncol       Date:  2019-06-21       Impact factor: 4.424

Review 6.  Peritoneal-plasma barrier.

Authors:  P Jacquet; P H Sugarbaker
Journal:  Cancer Treat Res       Date:  1996

7.  Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.

Authors:  C Demtröder; W Solass; J Zieren; D Strumberg; U Giger-Pabst; M-A Reymond
Journal:  Colorectal Dis       Date:  2016-04       Impact factor: 3.788

8.  Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.

Authors:  Y L B Klaver; L H J Simkens; V E P P Lemmens; M Koopman; S Teerenstra; R P Bleichrodt; I H J T de Hingh; C J A Punt
Journal:  Eur J Surg Oncol       Date:  2012-05-08       Impact factor: 4.424

9.  Single-port access for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): technique, feasibility and safety.

Authors:  Marco Vaira; Manuela Robella; Alice Borsano; Michele De Simone
Journal:  Pleura Peritoneum       Date:  2016-12-15

10.  Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.

Authors:  Wiebke Solass; Reinhold Kerb; Thomas Mürdter; Urs Giger-Pabst; Dirk Strumberg; Clemens Tempfer; Jürgen Zieren; Matthias Schwab; Marc André Reymond
Journal:  Ann Surg Oncol       Date:  2013-09-05       Impact factor: 5.344
View more
  3 in total

1.  Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.

Authors:  Abdelkader Taibi; Olivia Sgarbura; Martin Hübner; Sylvia M Bardet; Mohammed Alyami; Naoual Bakrin; Sylvaine Durand Fontanier; Clarisse Eveno; Johan Gagniere; Basile Pache; Marc Pocard; François Quenet; Hugo Teixeira Farinha; Emilie Thibaudeau; Frederic Dumont; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2022-03-22       Impact factor: 4.339

2.  Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases.

Authors:  Aurélie Balmer; Daniel Clerc; Laura Toussaint; Olivia Sgarbura; Abdelkader Taïbi; Martin Hübner; Hugo Teixeira Farinha
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

Review 3.  Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma Peritonei: A Literature Review.

Authors:  Suiting Ye; Song Zheng
Journal:  Am J Clin Oncol       Date:  2022-04-14       Impact factor: 2.787
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.